ProCE Banner Activity

RELEVANCE: Phase III Study of Lenalidomide + Rituximab vs Chemotherapy + Rituximab in Untreated Follicular Lymphoma

Slideset Download
Conference Coverage
Lenalidomide plus rituximab did not improve CR rate or PFS over chemotherapy plus rituximab but was associated with lower rates of neutropenia and febrile neutropenia.

Released: June 06, 2018

Expiration: June 05, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen